virtual lectures planning committee disclosure summary · virtual lectures planning committee...
TRANSCRIPT
© MFMER© MFMER
VIRTUAL LECTURES
THE ROLL OF MEDICAL CANNABIS: IS IT TIME TO BURN ONE DOWN?
© MFMER
Virtual Lectures Planning Committee Disclosure Summary As a provider accredited by ACCME, College of Medicine, Mayo Clinic (Mayo School of CPD) must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.
Relevant financial relationship(s) with industry: None
References to off-label and/or investigational usage(s) of pharmaceuticals or instruments in their presentation: None
Listed below are individuals with control of the content of this program who have disclosed:
Program SpeakerThomas Pittelkow, D.O., M.P.H.
Program Planning CommitteeCurtis Hanson, M.D.Bobbi Pritt, M.D., MSc, DTMHSharon PreussMelissa Peterson
© MFMER
Thomas Pittelkow, D.O., M.P.H.
Department of Anesthesiology-Pain MedicineMayo ClinicRochester, Minnesota
Senior Associate Consultant, Pain Clinic
©2016 MFMER | slide-4
The roll of medical cannabis:Is it time to burn one down?
Thomas P. Pittelkow, D.O., M.P.H.Division of Pain MedicineDepartment of Anesthesiology and Perioperative Medicine
October 4, 2017
©2016 MFMER | slide-5
Disclosures
Relevant Financial Relationship(s)
None
Off Label Usage
Medical cannabis is not FDA-approved
Products produced by:
Minnesota Medical Solutions
Leafline Labs
©2016 MFMER | slide-6
©2016 MFMER | slide-7
©2016 MFMER | slide-8
Learning Objectives
• Identify the key cannabinoids, receptors, and basic physiology of medical cannabis
• Specify conditions where use of medical cannabis is potentially indicated
• Articulate role of medical cannabis in pain treatment algorithm
©2016 MFMER | slide-9
Medical Potential
• Over 20,000 published articles on cannabinoids• Evidence for symptom relief
• Nausea and vomiting – chemotherapy• Pain – neuropathic/central• Muscle spams - MS• Spasticity - MS• Cachexia – HIV/AIDS• Mental health – anxiety, PTSD, etc.
• Significant potential role in chronic pain and multiple chronic health conditions
©2016 MFMER | slide-10
Framework
• History
• Physiology
• Rx Cannabinoids
• Minnesota Registry
• Indications• Pain• Spasticity
• Considerations
• Summary
©2016 MFMER | slide-11
Case
• 35 year-old Female, MN resident
• Hormone receptor positive, HER-2 negative, metastatic breast carcinoma
• Metastases to the liver, lung and bone
• Multiple symptoms• Cancer-associated pain, mixed-type• Nausea• Anorexia• Insomnia• Fatigue
©2016 MFMER | slide-12
Reflection
• Would you certify this patient?
©2016 MFMER | slide-13
©2016 MFMER | slide-14
Patient perspectives
• Social media
• Traditional medication side effects
• Stigma of “strong medicine”• Fears – dependence, addiction
• Mistrust
• Natural medicine
• Alleviate suffering
• Hope
©2016 MFMER | slide-15
Physician considerations
• Adequate current medication regimen?
• Expert for complex symptom management?
• Pharmacotherapy interactions?
• Psychosocial and financial domains?
• Prior substance abuse/dependence?
• Routine follow-up?
©2016 MFMER | slide-16
©2016 MFMER | slide-17
History of Cannabis and Opioids
Early use in China
3000 B.C.
O’Shaughnessy -Testing in disease;Therapeutic potential
1800’s 1900’s
1937 Marihuana Tax Act
1940Synthetic form devised
THC identified psychoactive component
1964
Controlled Substances Act
1970CA 1st state to legalize medical cannabis
1996
500 B.C.
Reference to opium elixir
1500’s
Opium elixir for analgesia
1804Opium extracted from poppy
1817Morphine marketed in Germany
1900’sSynthetic morphine equivalents devised
1970Opioid receptors discovered
1975Endogenous opioids -endorphins
CO and WA 1st state to legalize recreational cannabis
2012
1914Harrison Act -Prohibited Rx of opiates to addicts
1990sIncrease in opioid prescriptions
1999Rise of opioid-related deaths
©2016 MFMER | slide-18
Anatomy of a Cannabis Plant
©2016 MFMER | slide-19
What makes those buds so special?• Nearly 500 natural compounds in the Cannabis sativa plant
• Over 70 cannabinoids• Delta-9-tetrahydrocannabinol (THC)
• Psychoactive component• Euphoria, hallucinations, tachycardia, anxiety
• Cannabidiol (CBD)• Analgesia• Neuroprotective• Anti-inflammatory
• Anandamide• Endogenous cannabinoid• Glutamatergic and GABA-ergic• Pain, muscle tone, emotion
©2016 MFMER | slide-20
The Endocannabinoid System
CB1 receptor
(THC)
CB2 receptor
(CBN)
eCB = endocannabinoid; produced by the body
CBD - Cannabidiol • Inhibits the breakdown of
anandamide (FAAH)• Microglial cell activation
©2016 MFMER | slide-21
The Endocannabinoid System
CB1 receptor
(THC)
CB2 receptor
(CBN)
• Primarily in brain, spinal cord, peripheral nerves, GI and reproductive tract
• Highly expressed in immune tissues
• Regulate cytokine release
• ? Role in pain
©2016 MFMER | slide-22
Microenvironment Direct inhibitor: ACh, DA, Glut
Indirect effect: GABA, NMDA, μ, 5-HT
©2016 MFMER | slide-23
Fountain of Youth
Tre
nds
Pha
rmac
olS
ci. 2
009
Oct
;30(
10):
515-
27.
©2016 MFMER | slide-24
©2016 MFMER | slide-25
Cannabis derived products
• Dronabinol (Marinol ®)
• Nabilone (Cesamet ®)
• Nabiximols (Sativex ®)
• Cannador
• Epidiolex
©2016 MFMER | slide-26
Dronabinol (Marinol ® )
• Synthetic THC (no CBD)
• Oral capsule
• Schedule III Controlled Substance
• FDA approved indications: • Treatment of anorexia associated with weight loss in
patients with AIDS• Treatment of nausea and vomiting associated with
cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments
©2016 MFMER | slide-27
Nabilone (Cesamet ® )
• Synthetic analogue of THC
• Oral capsule
• Schedule II Controlled Substance
• FDA approved indication:• Treatment of nausea and vomiting
associated with cancer chemotherapy in patients who have failed to respond adequately to conventional therapy
©2016 MFMER | slide-28
Nabiximols (Sativex ® )
• Oromucosal spray
• Not available in the USA
• Whole plant extract (phytocannabinoid)
• 1:1 ratio of THC:CBD
• 100 microliter spray (2.7mg THC, 2.5mg CBD)
• Approved for pain treatment in >24 countries
• Phase 3 clinical trials in US
©2016 MFMER | slide-29
Cannador
• THC:CBD combination (~2:1 ratio)
• Oral capsule
• Phytocannabinoid
• Prominent psychoactive side effects
• Not available in the USA
©2016 MFMER | slide-30
Epidiolex ®
• Liquid formulation of pure plant-derived cannabidiol (CBD), no THC
• Treatment of pediatric epilepsy syndromes • Dravet, Lennox-Gastaut, Infantile Spasms• Phase 3 clinical trials
©2016 MFMER | slide-31
The Reviews
• Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
• JAMA. 2015;313(24):2456-2473.
• Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review
• JAMA. 2015;313(24):2474-2483.
• The Effects of Cannabis Among Adults With Chronic Pain and an Overview of General Harms: A Systematic Review
• Ann Intern Med. 2017;167:319-331.
• The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research
• The National Academies Press, 2017
©2016 MFMER | slide-32
The Evidence of Cannabinoid Efficacy
• Conclusive quality evidence • Chronic pain (neuropathic) • Spasticity (MS)• Nausea, chemotherapy-induced
• Moderate quality evidence• Improved short-term sleep outcomes
• Limited quality evidence• Weight gain in serious illness (HIV, Cancer)• Improved symptoms of anxiety or PTSD
JAMA. 2015;313(24):2456-2473.JAMA. 2015;313(24):2474-2483.Ann Intern Med. 2017;167:319-331.The Health Effects of Cannabis and Cannabinoids. National Academies Press. 2017
©2016 MFMER | slide-33
©2016 MFMER | slide-34
Current Cannabis State Laws
©2016 MFMER | slide-35
Minnesota Medical Cannabis Program
©2016 MFMER | slide-36
Minnesota – 11 Qualifying Conditions• Cancer associated with severe/chronic pain, nausea or severe vomiting, or cachexia
or severe wasting
• Glaucoma
• HIV/AIDS
• Tourette’s Syndrome
• Amyotrophic Lateral Sclerosis (ALS)
• Seizures, including those characteristic of epilepsy
• Severe and persistent muscle spasms, including those characteristic of Multiple Sclerosis
• Crohn’s Disease
• Terminal illness, with a life expectancy of less than one year, if the illness or treatment produces severe/chronic pain, nausea or severe vomiting, cachexia or severe wasting
• Intractable pain
• Post-Traumatic Stress Disorder
Use of medical cannabis products is experimental
©2016 MFMER | slide-37
Minnesota – Certification
• Physicians, physician’s assistants, and advanced practice registered nurses
• MDH will not maintain or publish a list of practitioners who certify
• Practitioners do not have to participate in certifying patients
• Practitioners will not determining strength of medical cannabis
• Practitioners must have registry account
©2016 MFMER | slide-38
Minnesota - No Prescription Needed
• Federal policy dictates that physician who prescribes marijuana or other Schedule I drugs to a patient may be stripped of his or her federal license to prescribe drugs and prosecuted
• “Recommend” or “certify”
©2016 MFMER | slide-39
Minnesota - Medical Cannabis Industry
©2016 MFMER | slide-40
Minnesota – Dispensary
• Pharmacist works with patient to determine an appropriate cannabis dose
• Disease• Symptoms• Tolerable side-effects
• MN 2nd state to use pharmacists to dispense
• No guidelines for pharmacists to dose different medical conditions
• Based on genetic strain• THC:CBD
©2016 MFMER | slide-41
Minnesota – Methods of Delivery
• Edibles – capsules, solutions, tinctures
• Topicals – balm, bars, patches
• Vaporization – prefilled cartridge, oil
• “Start low, go slow”
©2016 MFMER | slide-42
Mayo Clinic Policy
• Establish a medical relationship
• Full assessment of the patient's medical history and current medical condition
• Disclose experimental nature of therapeutic use of medical cannabis; risk, benefits, and side effects; Tennessen warning
• Patient will have regular follow-up for qualifying health condition with certifier
©2016 MFMER | slide-43
©2016 MFMER | slide-44
©2016 MFMER | slide-45
Organizational support
• IOM, AMA, ACP, ASAM• Support more research• Develop of safe and reliable delivery
systems• Reclassification of Class I status• Apply “established research standards”
©2016 MFMER | slide-46
Pills, joints, and the Volcano…
• Many ways for ingestion
• Different mediums = different [THC]• Flowers/buds – 2-10%• Hash – 30%• Shatter – 80%
• Bioavailability – large first pass effect• PO – 10-20%• Inhalation – 30-50%
• THC – metabolized by CYP2C9 and CYP3A4
©2016 MFMER | slide-47
Research - Pain
©2016 MFMER | slide-48
Pain Treatment – Early Years
• Research in animal models beneficial effect• Chemical, mechanical, thermal pain stimuli• Chronic pain of neuropathic and
inflammatory origin
• Endocannabinoids exert synergistic anti-nociceptive effects when combined with NSAIDs
• Functional interplay between endocannabinoid and opioid receptor systems in modulating analgesic responses
British Jour of Pharmacology. 2016. 173(16): 2521-31. Trends in Pharm Sci. 2015. 36(5): 277-296.Eur J Pharmacol. 2007. 556:75-83Pain. 2004. 109:124-131.
©2016 MFMER | slide-49
Pain Treatment – Rx Cannabinoids
• Nabiximols reduced neuropathic pain in patients• Traumatic peripheral nerve injury (allodynia)• Multiple sclerosis
• Dronabinol provided modest analgesic effects in multiple sclerosis
• Orally administered cannabis extract (THC) effective in pain relief
• Analgesic efficacy of smoked cannabis in treating neuropathic pain
Clin Rehab. 2003. 17(1):21-9.Anaesthesia. 2004. 59(5):440-52.BMJ. 2004. 31;329(7460):253. Lancet. 2003. 8;362(9395):1517-26.Neurology. 2005. 27;65(6):812-9.
©2016 MFMER | slide-50
Synergistic Effect with Opioids
• Lesser of two evils• Chronic pain – stable systemic opioid therapy• Inhaled vaporized cannabis• Significant decrease in pain with cannabis
• Either-or model• States with medical cannabis laws - 25%
lower mean annual opioid-overdose mortality
• Better together• Opioid with cannabinoid receptor agonist
reduced nerve injury-induced allodynia
Clin Pharmacol Ther. 2011. 90(6):844-51JAMA Intern Med. 2014. 174(10):1668-73.Br J Pharmacol. 2016. 173(16):2521-31.
©2016 MFMER | slide-51
Research - Spasticity
©2016 MFMER | slide-52
Cannabis as Treatment for Spasticity
• Most trials have been in patients with multiple sclerosis
• Multiple studies showing benefit in reduction of MAS and functional gains
• Decrease in sleep disruption
• Precise ratio of THC:CBD is not clear
• ? Safety and potential long-term effects on cognitive function
Eur J Neurol. 2011. 18(9):1122-31. Mult Scler. 2012. 18(2):219-28. Neurol Res. 2010. 32(5):451-9.
©2016 MFMER | slide-53
High times for research
• Challenges with separation of social and medical policies
• Funding for cannabis research
• Growing body of evidence supporting benefit
• Studies with little-to-no benefit demonstrate that cannabis is relatively safe
• Low-moderate doses are typically well tolerated, especially when spread over time
©2016 MFMER | slide-54
©2016 MFMER | slide-55
Risks?
• ‘Marijuana doesn’t have any risks—it’s a flower. It’s not like morphine.’ – Dispensary Owner
©2016 MFMER | slide-56
Expectations, Risks, and Drug Interactions
• Common side effects• Dizziness• Tiredness• Confused• Lose touch with reality• Memory impairment• Trouble concentrating
• Driving impairment
• Addiction
• Stroke, MI, mental health disorders
• Drug Interactions• Evidence for synergy
with opioids• Benzodiazepines and
other sedatives• Antidepressants• Warfarin and
anticoagulants• NSAIDs (COX2-
selective)
• Not recommended for pregnant or nursing women
©2016 MFMER | slide-57
So, that’s what the future looks like…
• Expansion of state-based approval with variety of laws and regulations
• Ongoing research and clinical trials• Anti-proliferative effect
• Responsibility to stay current with legislation, regulations, and medical advancement in respective area of practice
• Encourage regular collaboration with patients and pharmacists
• Dosages• Side-effects • Symptom control
©2016 MFMER | slide-58
What happened…
• 35 yo Female with metastatic breast cancer• Continues to get treatment• Holistic and natural care focus• Rick Simpson cannabis (C. indica)• IDD for pain (turned off)
©2016 MFMER | slide-59
In Summary
• Medical cannabis• Delta-9-tetrahydrocannabinol (THC)• Cannabidiol (CBD)
• Best evidence – depends on perspective• Intractable central/neuropathic pain• MS associated spasticity and pain related to
muscle spasms
• There is no formally accepted role for the use of medical cannabis in typical treatment algorithm
• If all else fails…
©2016 MFMER | slide-60
©2016 MFMER | slide-61
Interesting Reads• University of California – San Diego, Medical Cannabis Research Center http://www.cmcr.ucsd.edu/
• Health Canada document for physicians: http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/marihuana/med/infoprof-eng.pdf
• Minnesota Department of Health – A Review of Medical Cannabis Studies http://www.health.state.mn.us/topics/cannabis/practitioners/dosage.pdf
• The University of Washington Alcohol and Drug Abuse Institute. http://learnaboutmarijuanawa.org/factsheets/cannabinoids.htm
• The American Cancer Society, “Marijuana and Cancer.” http://www.cancer.org/treatment/treatmentsandsideeffects/complementaryandalternativemedicine/herbsvitaminsandminerals/marijuana
• The National Cancer Institute at the National Institutes of Health. Cannabis and Cannabinoids. http://www.cancer.gov/cancertopics/pdq/cam/cannabis/healthprofessional/
• International Association for Cannabinoid Medicines, http://www.cannabis-med.org/index.php?lng=en
• The National Academies of Sciences, Engineering, and Medicine . The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research (2017). https://www.nap.edu/catalog/24625/the-health-effects-of-cannabis-and-cannabinoids-the-current-state
©2016 MFMER | slide-62
References• Izzo AA, et al. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends
Pharmacol Sci. 2009 Oct;30(10):515-27.
• Whiting PF, et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015 Jun 23-30;313(24):2456-73.
• Hill KP. Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review. JAMA. 2015 Jun 23-30;313(24):2474-83.
• Pacher P, et al. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006 Sep;58(3):389-462.
• Wade DT, et al. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil. 2003 Feb;17(1):21-9.
• Notcutt W, et al. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies. Anaesthesia. 2004 May;59(5):440-52.
• Aggarwal SK and CD Blinderman. Cannabis for symptom control #279. J Pall Med. 2014 May;17(5):612-4.
• Carter GT, et al. Cannabis in palliative medicine: improving care and reducing opioid-related morbidity. Am J Hosp PalliatCare. 2011 Aug;28(5):297-303.
• Abrams D and M Guzman. Cannabis in cancer care. Clin Pharmacol Ther. 2015 Jun;97(6):575-86.
• Wilsey B, et al. The Medicinal Cannabis Treatment Agreement: Providing Information to Chronic Pain Patients Through a Written Document. Clin J Pain. 2015 Dec;31(12):1087-96.
• Pacher P, et al. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006 Sep;58(3):389-462.
©2016 MFMER | slide-63
References• Svendsen KB, et al. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind
placebo controlled crossover trial. BMJ. 2004 Jul 31;329(7460):253.
• Zajicek J, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003 Nov 8;362(9395):1517-26.
• Rog DJ, et al. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005 Sep 27;65(6):812-9.
• Wilsey B, et al. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain. 2008 Jun;9(6):506-21.
• Serpell M, et al. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. Eur J Pain. 2014 Aug;18(7):999-1012.
• Abrams DI, et al. Cannabinoid-opioid interaction in chronic pain. Clin Pharmacol Ther. 2011 Dec;90(6):844-51.
• Bachhuber MA, et al. Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. JAMA Intern Med. 2014 Oct;174(10):1668-73.
• Wilsey B, et al. Low-dose vaporized cannabis significantly improves neuropathic pain. J Pain. 2013;14(2):136-48.
• Noyes R Jr, et al. Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol. 1975. 15(2-3):139-43.
• Noyes R Jr, et al. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther. 1975. 18(1):84-9.
• Johnson JR, et al. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage. 2010. 39(2):167-79.
©2016 MFMER | slide-64
References• Johnson JR, et al. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD
oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J Pain Symptom Manage. 2013 Aug;46(2):207-18.
• Portenoy RK, et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain. 2012. 13(5):438-49
• Novotna A, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. 2011. 18(9):1122-31.
• Notcutt W, et al. A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols). Mult Scler. 2012. 18(2):219-28.
• Collin C, et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res. 2010. 2(5):451-9.
• Wilsey B, et al. The Medicinal Cannabis Treatment Agreement: Providing Information to Chronic Pain Patients via a Written Document. Clin J Pain. 2015. 31(12):1087-96
• Koppel BS et al., Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014 Apr 29;82(17):1556-63.
• Fife TD et al. Clinical perspectives on medical marijuana (cannabis) for neurologic disorders. Nuerol Clin Pract. 2015 Aug;5(4):344-351.
• Schrot RJ and JR Hubbard. Cannabinoids: Medical implications. Ann Med. 2016, Feb 25:1-14. (Epub ahead of print)
• Bolognini D and RA Ross. Medical cannabis vs. synthetic cannabinoids: What does the future hold? Clin Pharmacol Ther. 2015 Jun;97(6):568-70.